T1	Participants 592 758	arm A, patients received 12-week bevacizumab plus 5-FU, leucovorin and oxaliplatin (Folfox-4) followed with bevacizumab-5-FU-RT before total mesorectal excision (TME)
T2	Participants 763 823	arm B, patients received only bevacizumab-5-FU-RT before TME
T3	Participants 898 966	Forty-six patients were randomized in arm A and 45 patients in arm B
T4	Participants 1309 1361	Postoperative fistulas were reported for 16 patients
